Exabis Library
Welcome to the e-CCO Library!
P711 Carriage of the HLA-DQA1*05 allele is associated with a high risk of loss of response to adalimumab in patients with Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P711: A pilot study using point of care testing for infliximab and faecal calprotectin in IBD patients with a secondary loss of response
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P711: Decreased steroid exposure and disease-related hospitalizations in patients with newly diagnosed inflammatory bowel disease in the era of newer biologic agents – A multi-centre experience in Singapore.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P711: Stool microbiome communities predict remission in pediatric Crohn’s disease patients even after start of treatment
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P711: The real-life experience of vedolizumab therapy in the OBSERV-IBD cohort: a 3-year prospective observational multi-centre cohort study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P711: Vegetarian or gluten-free diet in patients with IBD – associated with lower psychological well-being and quality of life but no indication of beneficial effects on course of disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P712 Association of histologic-endoscopic mucosal healing after ustekinumab induction or maintenance therapy with 2-year outcomes in the UNIFI Phase 3 study in ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P712: Establishing pharmacokinetic equivalence between adalimumab and ABP 501 in the presence of anti-drug antibodies using population PK modelling
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P712: Fungal microbiota composition in Inflammatory Bowel Disease patients in a Norwegian cohort: characterization of disease phenotypes and correlation with clinical activity and disease course.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P712: Real-World Efficacy And Safety Of Ustekinumab And Adalimumab In Patients With Crohn's Disease: Propensity Matched Analysis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P712: Risk factors for the development of fistulae and stenoses in Crohn's disease patients in the Swiss IBD cohort
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P712: Tofacitinib efficacy in patients with moderate to severe ulcerative colitis: Subgroup analyses of OCTAVE Induction 1 and 2 and OCTAVE Sustain by 5-aminosalicylates use
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P713 Effects of vedolizumab on health-related quality of life, work productivity and patient concerns in patients with ulcerative colitis and Crohn’s disease in the UK and Ireland: OCTAVO cohort 2
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P713: Gut microbiota alterations after bowel preparation amongst inflammatory bowel disease patients
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P713: Home-based vedolizumab infusions: A suitable alternative to routine hospital infusions
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P713: Long-term efficacy of endoscopic balloon dilatation using single-balloon enteroscopy in patients with Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P713: Possible explanations of the marked differences in the incidence of microscopic colitis between Denmark and Sweden
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P713: Proactive therapeutic infliximab monitoring during induction phase in inflammatory bowel disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P714 Real-world effectiveness of vedolizumab in ulcerative colitis: Week 52 results from the Swedish multi-centre, prospective, observational SVEAH UC study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P714: Comparison of intestinal microbiota profiles of faecal samples, rectal swabs and mucosal biopsies in patients with Inflammatory Bowel Disease. A multicentre, observational study.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM